This market study from Technavio segments the global conjunctivitis market by disease type (bacterial conjunctivitis, viral conjunctivitis, and allergic conjunctivitis) and by geography (APAC, EMEA, and the Americas). The report also provides an analysis of the key trends and vendors in this market, including Akorn, Alcon, Allergan, and Bausch & Lomb.
Technavio’s market research analysts estimate the global conjunctivitis market, to grow at a CAGR of around 2% between 2015 and 2019. Though the incidence of conjunctivitis or pink eye is high, the rate of treatment use is not, as the infection usually heals on its own. Factors such as the growing awareness among consumers and the widespread availability of multiple treatment options will spur the prospects for growth in the pink eye treatment market. The Americas account for 51% of the conjunctivitis market, due to the increasing awareness of the infection coupled with the availability of treatment options
The new market research report from Technavio provides a breakdown and analysis of the conjunctivitis segments by technology.
Source: Technavio: 2015
“Since there are no approved drugs for the treatment of viral conjunctivitis, many companies and researchers are now developing drugs that are in the clinical stage of development. These drugs are expected to aid in the treatment of viral conjunctivitis and their effectiveness will in turn promote growth in this market in the next four years,” says Imran Mushtaq, Industry Manager, Healthcare & Lifesciences, Technavio Research.
Technavio’s market research analyst has estimated the allergic conjunctivitis segment to account for more than 41% of the total market share by 2019. This condition is caused due the different allergens present in the environment and generally leads to constant irritation and inflammation of the conjunctival tissue.
The leading vendors in the global conjunctivitis market include Akorn, Alcon, Allergan, and Bausch & Lomb. This market is growing at a moderate pace owing to the loss of patent exclusivities and the augmented use of generics in the market. Since there is no effective treatment option for conjunctivitis, the companies that can effectively treat and cure this disease are expected to gain a competitive edge over their peers during the forecast period.
A more detailed analysis is available in the Technavio report, Global Conjunctivitis Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other related reports:
